9 terminated. 9 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Terminated 9 |
| Phase 1 | 2 | Terminated 2 |
| Phase 3 | 1 | Terminated 1 |
Follow Systemic Sclerosis: new trials by email Literature Review of Systemic Sclerosis trials Research Report on Systemic Sclerosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis KYV-101, Standard lymphodepletion regimen - Systemic Sclerosis, Systemic Sclerosis - Diffuse Cutaneous | Phase 1 / Phase 2 | Terminated | Kyverna Therapeutics | 3 | 2024-08-06 | 2026-08-31 |
| Efficacy and Safety of Riociguat in Incipient Pulmonary Vascular Disease as an Indicator for Early PAH Riociguat Oral Tablet, Placebo - Pulmonary Vascular Disorder, Primary Pulmonary Hypertension | Phase 2 | Terminated | Heidelberg University | 35 | 2022-10-24 | 2026-01-21 |
| A Study to Evaluate the Safety and Tolerability of Oral Ixazomib in Scleroderma-related Lung Disease Patients Ixazomib - Systemic Sclerosis, Scleroderma | Phase 2 | Terminated | Michael M. Pham | 4 | 2021-04-28 | 2025-04-06 |
| A Clinical Study to Test Long Term Safety of GLPG1690 for Patients With Systemic Sclerosis GLPG1690 - Systemic Sclerosis | Phase 2 | Terminated | Lakefront Biotherapeutics NV | 31 | 2019-07-18 | 2022-03-29 |
| Cardiac Safe Transplants for Systemic Sclerosis Rituximab, Fludarabine, Cyclophosphamide - Systemic Sclerosis, Scleroderma | Phase 2 / Phase 3 | Terminated | Northwestern University | 9 | 2018-05-17 | 2020-08-12 |
| Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Patients With Systemic Sclerosis With Interstitial Lung Disease Pomalidomide (CC-4047), Placebo - Scleroderma, Systemic, Sclerosis, Systemic | Phase 2 | Terminated | Celgene | 23 | 2012-08-09 | 2023-12-01 |
| Open-Label Study of Oral Treprostinil in Digital Ulcers treprostinil diethanolamine - Systemic Sclerosis | Phase 2 | Terminated | United Therapeutics | 115 | 2009-09-01 | 2024-06-18 |
| Effectiveness of UVA1-irradiation in the Treatment of Early Skin Fibrosis in Patients Suffering From Systemic Sclerosis UVA1 - Systemic Scleroderma, Systemic Sclerosis | Phase 1 / Phase 2 | Terminated | Nicolas Hunzelmann | 9 | 2008-02-01 | 2017-05-31 |
| Effect of Different Iloprost Doses on Symptoms in Systemic Sclerosis iloprost, iloprost low dose, iloprost therapy up to 2 ng/kg x min - Systemic Sclerosis | Phase 2 | Terminated | Charite University, Berlin, Germany | 50 | 1997-09-01 | 2008-02-25 |
Scleroderma, Systemic (9) · Scleroderma, Diffuse (4) · Lung Diseases, Interstitial (2) · digital ulcers (2) · Autoimmune Diseases (1) · Familial Primary Pulmonary Hypertension (1) · Hypertension, Pulmonary (1) · Pulmonary Fibrosis (1) · Vascular Diseases (1)
Connective Tissue Diseases (9) · Skin Diseases (9) · Skin and Connective Tissue Diseases (9) · Lung Diseases (3) · Respiratory Tract Diseases (3) · Cardiovascular Diseases (2) · Fibrosis (1) · Hypertension (1) · Immune System Diseases (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Vascular Diseases (1)
Cyclophosphamide (2) · fludarabine (2) · Antilymphocyte Serum (1) · Filgrastim (1) · GLPG1690 (1) · Granulocyte Colony-Stimulating Factor (1) · Iloprost (1) · Immunoglobulins, Intravenous (1) · Mesna (1) · Methylprednisolone (1) · Methylprednisolone Acetate (1) · Methylprednisolone Hemisuccinate (1) · Octagam (1) · Rituximab (1) · Ultraviolet Rays (1)
Celgene (1) · Charite University, Berlin, Germany (1) · Heidelberg University (1) · Kyverna Therapeutics (1) · Lakefront Biotherapeutics NV (1) · Michael M. Pham (1) · Nicolas Hunzelmann (1) · Northwestern University (1) · United Therapeutics (1)
United States (6) · Germany (4) · United Kingdom (4) · Italy (3) · France (2) · Spain (2) · Switzerland (2) · Australia (1) · Austria (1) · Belgium (1) · Canada (1) · Poland (1) · Russia (1)
Gabriela Riemekasten, MD (1) · James Seibold, MD (1) · Michael Pham, MD (1) · Nicolas Hunzelmann (1) · Richard Burt, MD (1) · Shimon Korish, MD (1)
PMID 18634152, PMID 32612255, PMID 42457022
2019 (1)